RYTELO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYTELO (RYTELO).
RYTELO (omaveloxolone) is an activator of nuclear factor erythroid 2-related factor 2 (NRF2), a transcription factor that regulates the expression of antioxidant and anti-inflammatory genes. By activating NRF2, omaveloxolone enhances the production of detoxification enzymes and reduces oxidative stress and inflammation in mitochondria.
| Metabolism | Omaveloxolone is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C8 and CYP2C9. |
| Excretion | Primarily renal excretion, with ~70% of the dose eliminated unchanged in urine; ~20% recovered in feces as metabolites; minor biliary contribution (<5%). |
| Half-life | Terminal elimination half-life is approximately 18–24 hours in patients with normal renal function, allowing once-daily dosing; prolonged (up to 50 hours) in severe renal impairment. |
| Protein binding | Approximately 92% bound to plasma proteins, primarily albumin and α1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.8–1.2 L/kg, indicating distribution throughout total body water with moderate tissue binding. |
| Bioavailability | Subcutaneous: absolute bioavailability is approximately 60% (range 50–70%); oral: low and variable (<10%), not used clinically. |
| Onset of Action | Subcutaneous: Peak plasma concentrations reached within 4–6 hours; clinical effect (symptom improvement in pruritus) observed within 1–2 weeks. |
| Duration of Action | Duration of clinical effect is approximately 24 hours, supporting once-daily administration; sustained response observed with continuous therapy. |
400 mg orally twice daily with food.
| Dosage form | POWDER |
| Renal impairment | For GFR 15-29 mL/min, reduce dose to 200 mg twice daily. For GFR <15 mL/min not on dialysis, avoid use. |
| Liver impairment | Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose to 200 mg twice daily. Child-Pugh class C: avoid use. |
| Pediatric use | Safety and efficacy not established; no recommended dose. |
| Geriatric use | No specific dose adjustment required; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYTELO (RYTELO).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions, advise patients not to breastfeed during treatment and for at least 1 week after last dose. |
| Teratogenic Risk | No human data. In animal studies, RYTELO (tagraxofusp) was not teratogenic at clinically relevant doses. However, due to mechanism of action (CD123-directed cytotoxin), potential for fetal harm exists. Use only if benefit outweighs risk. Avoid in pregnancy unless no alternative. |
■ FDA Black Box Warning
None
| Serious Effects |
["Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort)"]
| Precautions | ["Hepatotoxicity: Elevations in liver enzymes (ALT/AST) have been observed; monitor liver function tests before and during treatment.","Lipid abnormalities: Increases in total cholesterol, LDL cholesterol, and triglycerides may occur; monitor lipid profile.","Drug interactions: Avoid concomitant use with strong CYP3A4 inducers; use with caution with moderate CYP3A4 inhibitors.","Fetal/Neonatal toxicity: Based on animal data, may cause fetal harm; advise females of reproductive potential to use effective contraception."] |
Loading safety data…
| Fetal Monitoring |
| Monitor for capillary leak syndrome (CLS) symptoms (hypotension, edema, hypoalbuminemia) before each dose. Assess serum albumin, vital signs, weight. If CLS occurs, hold or discontinue. No specific fetal monitoring required but consider obstetrical consultation if used. |
| Fertility Effects | No human fertility studies. In animal studies, no effects on male or female fertility were observed. However, due to cytotoxic mechanism, potential for impairment of reproductive function cannot be excluded. |